The purpose of this commentary is to highlight this new model for sarcolemmal nNOSμ localization and to discuss its implications in the context of ongoing clinical testing of the ability of miniaturized dystrophins to mitigate dystrophic pathology in individuals with DMD. This evidence concerns the gene DMD and Duchenne muscular dystrophy.